Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    9 0 0 0


Archives de pédiatrie
Volume 18, n° S1
pages 33-41 (mai 2011)
Doi : 10.1016/S0929-693X(11)70938-1
Les échinocandines chez l’enfant Echinocandins in children
 

G. Leverger 1, , N. Le Guyader 2
1 Service d’hématologie-oncologie pédiatrique, Hôpital Armand-Trousseau, 26, avenue du Docteur-Arnold-Netter, 75012 Paris, France 
2 Service pharmacie, Groupe Hospitalier Diaconesses-Croix-Saint-Simon, 18, rue du Sergent-Bauchat, 75020 Paris, France 

Auteur correspondant.
Résumé

Les échinocandines sont une classe d’antifongiques systémiques présentant un mode d’action spécifique. Ces molécules interfèrent avec la synthèse de la paroi fongique par inhibition de la 1,3β – D-glucane synthétase, enzyme présente chez la plupart des champignons pathogènes. Leur spectre d’action est étendu vis-à-vis des Candida et des Aspergillus . Trois molécules sont actuellement disponibles ou en cours de développement : la caspofungine, la micafungine et l’anidulafungine. Ces médicaments sont administrés par voie intraveineuse. Leur efficacité, leur bonne tolérance, la rareté des interférences médicamenteuses, ainsi que la spécificité de leur site d’action en font des molécules de choix pour le traitement des infections fongiques systémiques. En France, la micafungine et la caspofungine ont une AMM chez l’enfant dans des indications spécifiques.

The full text of this article is available in PDF format.
Summary

Echinocandins are a new class of antifungal agents with a specific mechanism of action. These drugs inhibit the enzyme 1,3β – D-glucan synthetase which is responsible for the formation of 1,3β – D-glucan, an essential fungal cell wall component. They have a good activity against Candida species and Aspergillus . Three agents are available at the present time or under development : caspofungin, micafungin and anidulafungin. These drugs require intravenous administration. Efficacy, safety, rare drugs interactions and specificity of action are advantages for therapy of invasive fungal infections. In France, micafungin and caspofungin are approved for a pediatric use.

The full text of this article is available in PDF format.


© 2011  Elsevier Masson SAS. All Rights Reserved.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@